SCHW
65
-2
CNP
50
-2
NOC
40
-10
CSX
68
3
OXY
55
6
FLS
76
-2
AA
38
-2
FTI
78
-3
EXR
59
4
TROW
51
-2
EMN
50
-2
AES
41
2
GPC
40
2
SWKS
33
-10
DVN
29
4
MMM
42
5
SRE
66
-3
LB
63
-4
FOX
57
-3
CF
53
2
SCHW
65
-2
CNP
50
-2
NOC
40
-10
CSX
68
3
OXY
55
6
FLS
76
-2
AA
38
-2
FTI
78
-3
EXR
59
4
TROW
51
-2
EMN
50
-2
AES
41
2
GPC
40
2
SWKS
33
-10
DVN
29
4
MMM
42
5
SRE
66
-3
LB
63
-4
FOX
57
-3
CF
53
2
Financhill
Back

Cara Therapeutics Quote, Financials, Valuation and Earnings

Buy these stocks BEFORE President Trump returns to the Oval Office

See details on which stocks are poised to surge.
Sell
50

CARA
Cara Therapeutics

Last Price:
0.33
Seasonality Move:
3.84%

7 Day Trial

ALL ACCESS PASS

$ 7

America's enemies are regrouping & it may sucker punch your savings

Click here to learn more.

Cara Therapeutics Price Quote

$0.33
+0.00 (+0.64%)
(Updated: November 14, 2024 at 5:55 PM ET)

Cara Therapeutics Key Stats

Sell
50
Cara Therapeutics (CARA) is a Sell
Day range:
$0.32 - $0.34
52-week range:
$0.24 - $1.31
Dividend yield:
0%
P/E ratio:
0.00
P/S ratio:
1.69
P/B ratio:
1.61%
Volume:
639.3K
Avg. volume:
630.4K
1-year change:
-72.21%
Market cap:
$18.7M
Revenue:
$21M
EPS:
$-2.04

How Much Does Cara Therapeutics Make?

Is Cara Therapeutics Growing As A Company?

  • What Is Cara Therapeutics's Growth Rate Quarterly?
    Quarterly YoY revenue growth is -0.86%
  • What Is Cara Therapeutics's EPS Quarterly YoY Growth Rate?
    Quarterly, year-over-year diluted EPS growth rate is 0%

Cara Therapeutics Stock Price Performance

What Is Cara Therapeutics 52-Week High & Low?

Cara Therapeutics Price To Free Cash Flow

Data Unavailable

Is It Risky To Buy Cara Therapeutics?

  • How Much Debt Does Cara Therapeutics Have?
    Total long term debt quarterly is $0
  • How Much Cash Does Cara Therapeutics Have?
    Cash and short term investments quarterly total is $56.6M
  • What Is Cara Therapeutics’s Book Value Per Share?
    Book value per share is 0.21

Is Cara Therapeutics Cash Flow Positive?

  • What Is CARA Cash Flow From Operations?
    Cash flow from operations (TTM) is -$79.9M
  • What Is Cara Therapeutics’s Cash Flow From Financing?
    Cash flow from financing (TTM) is $36.3M
  • What Is Cara Therapeutics’s Cash Flow From Investing?
    Cash flow from investing (TTM) is $34.2M

Cara Therapeutics Return On Invested Capital

  • Is Management Doing A Good Job?
    CARA return on invested capital is -189.52%
  • What Is Cara Therapeutics Return On Assets?
    ROA measures how assets are converting to revenues and is -103.2%
  • What Is CARA Return On Equity?
    ROE is a measure of profitability and is -189.52%

Cara Therapeutics Earnings Date & Stock Price

Cara Therapeutics Competitors

  • Who Are Cara Therapeutics's Competitors?
    Below is a list of companies who compete with Cara Therapeutics or are related in some way:
    • Perspective Therapeutics Inc (CATX)
    • Cocrystal Pharma Inc (COCP)
    • Citius Pharmaceuticals Inc (CTXR)
    • Oragenics Inc (OGEN)
    • Alaunos Therapeutics Inc (TCRT)

Cara Therapeutics Dividend Yield

Cara Therapeutics Analyst Estimates

YoY Growth Past Surprise
EPS: 0% -33%
Revenue: -85.71% -15.56%

Analyst Recommendations

Buy Recommendations: 0
Hold Recommendations: 4
Sell Recommendations: 0
Price Target: 1.66
Upside from Last Price: 404.73%

Major Shareholders

  • How many CARA shares are owned by institutional investors?
    29.1M CARA shares are owned by institutional investors
  • How many CARA shares are owned by insiders?
    3.1M CARA shares are owned by insiders